Uterine Cancer Mortality on the Rise, but Research Remains Underfunded
Though mortality rates for uterine cancer are on the rise, research for this cancer is underfunded, a study suggests.
Diagnosis & Disease Information
PIK3CA and ARID1A May Be Therapeutic Targets in Advanced Cervical Cancer
PIK3CA and ARID1A may be targets for drug development in recurrent or metastatic cervical cancer, according to researchers.
More Lines of Chemotherapy Linked to Higher Risk of VTE in Ovarian Cancer
New research suggests that, for patients with ovarian cancer, the risk of VTE increases as patients receive more lines of chemotherapy.
Abortion Restrictions May Affect More than 20% of Pregnant Cancer Patients in the US
More than 20% of US patients diagnosed with cancer during pregnancy may be unable to terminate that pregnancy due to abortion laws in their state, a new study suggests.
Time Spent on Health Care for Endometrial Cancer Negatively Affects Quality of Life
Patients with advanced or recurrent endometrial cancer spend about 15% of their time addressing health care needs, and this time burden can have a negative effect on their quality of life, a study suggests.
Minimally Invasive Surgery Linked to Longer Survival in Advanced Ovarian Cancer
Patients with advanced ovarian cancer may live longer if they undergo minimally invasive surgery rather than laparotomy, a study suggests.
Overall Survival Similar With or Without Niraparib Maintenance in Ovarian Cancer
Niraparib maintenance does not improve overall survival in patients with platinum-sensitive recurrent ovarian cancer, updated data suggest.
Dostarlimab Plus Chemo Deemed New Standard Care for Endometrial Cancer
Adding dostarlimab to chemotherapy can improve outcomes in patients with primary advanced or recurrent endometrial cancer, a phase 3 trial suggests.
Durvalumab, Tremelimumab, and Chemo Deemed Active in Advanced Ovarian Cancer
The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.
Adavosertib Appears Active but Toxic in Advanced Uterine Cancer
Adavosertib is active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma, a phase 2 study suggests.
- Loading...
Loading...
Next post in SGO 2023
Loading... 
Loading...